Joshua Schimmer

Shares of MannKind Corp. (NASDAQ: MNKD) fall as much as 27.105% prior to Tuesday's Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Piper Jaffray analyst Joshua Schimmer noted that MannKind faces a "number of obstacles" in the U.S. Food and Drug Administration's (FDA) review of...

In a report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals plc (NASDAQ: GWPH) and raised the price target from $77.00 to $97.00. Schimmer mentioned new checks with specialists who were convinced that CBD has “meaningful utility” for...

In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer resumed coverage on Amgen Inc. (NASDAQ: AMGN) with an Overweight rating and a price target of $143.00. In the report, Piper Jaffrays says "We are resuming coverage of AMGN with an Overweight rating and $143 PT (representing 25%...

In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer resumed coverage of Alexion (NASDAQ: ALXN) with an Overweight rating and a price target of $172.00. In the report, Piper Jaffray says "We are resuming coverage of ALXN with an Overweight rating with a $172 price target. While...

In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer resumed coverage on BioMarin Pharmaceuticals (NASDAQ: BMRN) with an Overweight rating and set a price target of $87.00. In the report, Piper Jaffray says "We are resuming coverage of BMRN with an Overweight rating and $87 PT. The...

In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on Vanda Pharmaceuticals (NASDAQ: VNDA) and maintained a price target of $21.00. In the report, Piper Jaffray says "We are assuming coverage of VNDA from our Piper Jaffray colleague Charles Duncan...

In a report published Monday, Lazard Capital Markets analyst Joshua Schimmer reiterated a Buy rating and $22.00 price target on Vanda Pharmaceuticals (NASDAQ: VNDA). In the report, Lazard Capital Markets noted, “VNDA shares got hammered on Friday in part off a short report that makes multiple...

Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating for shares of Incyte Corporation (Nasdaq: INCY) with a price target in "in the high-teens". They said that with an SPA from the FDA for the INCB18424 Phase III program, Incyte Corporation is well on its way...

Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating of Gilead Sciences, Inc. (Nasdaq: GILD). The Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo hosted a conference call with an HIV specialist who was also an investigator in the Gilead Sciences quad...